Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Ovid Therapeutics ownership filing by Point72 group reports shared holdings of 1,903,943 common shares (including warrants) representing 1.3% of the outstanding stock. The statement, dated as of the close of business on March 31, 2026, attributes shared voting and dispositive power to Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen for the reported position.
The filing states the 1.3% figure is calculated on an aggregate base of 151,028,955 shares outstanding, which combines 131,874,634 shares reported as of March 16, 2026 and 19,154,321 shares issued in a private placement on March 17, 2026, and assumes exercise of the reported warrants.
Ovid Therapeutics ownership filing reports that Eventide Asset Management, LLC and related filers disclose a 12,773,577-share position in Ovid's common stock, representing 7.3% of outstanding shares as of March 31, 2026. The filing states Eventide holds these shares as investment adviser to the Eventide Healthcare & Life Sciences Fund.
The statement is filed on behalf of Eventide, Finny Kuruvilla, M.D., Ph.D., and Robin C. John and includes the Rule 13d-4 disclaimer that the individual filers disclaim beneficial ownership. The filing is a passive ownership disclosure under Schedule 13G.
Ovid Therapeutics (Common Stock) Schedule 13G reports that Sirenia Capital Management LP and Alex Silverstein together beneficially hold 18,031,333 shares (including shares issuable on warrants) representing 9.9% of the class, calculated on a 151,028,955 share base. The filing states 8,552,333 shares are issuable upon exercise of reported warrants but such exercises are limited by a 9.99% blocker, so the reporting persons cannot currently exercise all warrants to reach the full issuable amount.
Ovid Therapeutics Inc is reported as having 7,029,223 shares beneficially owned by Balyasny-affiliated reporting persons, representing 5.33% of the company's common stock based on 131,874,634 shares outstanding as of March 16, 2026. The filing states the holdings are held through investment vehicles (ADMF and APHC) and notes 1,496,150 shares issuable upon exercise of warrants and exercise blockers termed the "Beneficial Ownership Limitation" and the "Second Beneficial Ownership Limitation".
Ovid Therapeutics Inc. reports that Jeremy M. Levin beneficially owns 8,551,502 shares of the company's common stock, equal to 4.5% of the class. The filing breaks this position into direct holdings, entity holdings, warrants, and options exercisable within 60 days of March 31, 2026.
The outstanding share base used to calculate the percentage is 186,640,102 shares as reported in the company's Form 10-Q for the quarter ended March 31, 2026.
Affinity Asset Advisors and Michael Cho reported beneficial ownership of 15,635,484 shares of Ovid Therapeutics Inc. As of March 31, 2026, that holding represents approximately 9.1% of Ovid's common stock, including 4,999,166 shares issuable upon exercise of warrants. The filing states the adviser exercises sole voting and dispositive power over these shares pursuant to its role as investment manager and attributes the position to the adviser and Michael Cho.
Ovid Therapeutics Inc. reported a net loss of $17.0 million for the quarter ended March 31, 2026, wider than the $10.2 million loss a year earlier, as it increased investment in its epilepsy and CNS pipeline. Revenue was minimal, with no license or royalty income recognized this quarter versus $0.1 million in the prior-year period.
Research and development expenses rose to $11.2 million from $6.7 million, mainly driven by higher spending on OV329, the KCC2 library and OV4071. The company strengthened its balance sheet through an October 2025 private placement, warrant exercises, ATM sales and a March 2026 private placement, ending the quarter with $165.6 million in cash, cash equivalents and marketable securities and working capital of $144.4 million. Management believes this liquidity will fund operations for at least 12 months while Ovid advances multiple small-molecule programs for drug-resistant seizures and other brain disorders.
Ovid Therapeutics reported first quarter 2026 results and detailed progress across its neurology pipeline. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $165.6 million, not including an additional $27.3 million from April warrant exercises, and expects this cash to fund operations into 2029.
Ovid raised $60.0 million in gross proceeds from a March 2026 PIPE financing and received $53.9 million in gross proceeds from the full exercise of Series A warrants issued in an October 2025 private placement. In the quarter, research and development spending rose as OV329 and OV4071 advanced, leading to a net loss of $17.0 million, or $0.12 per share.
Clinically, OV329 showed favorable safety, tolerability and pharmacokinetics up to 9 mg, supporting planned Phase 2 studies in treatment-resistant focal onset seizures, with additional programs planned in tuberous sclerosis complex seizures and infantile spasms. Ovid also dosed the first healthy volunteer in a Phase 1 study of OV4071, its first oral KCC2 direct activator, and outlined broader KCC2 portfolio plans in multiple CNS disorders.
Ovid Therapeutics Inc. has released its 2026 proxy statement for a fully virtual annual meeting on June 10, 2026 at 10:30 a.m. Eastern Time. Stockholders of record as of April 15, 2026, holding 173,037,131 common shares in total, may vote.
Investors are asked to elect one Class III director (Jeremy M. Levin), approve on an advisory basis the compensation of named executive officers, and ratify KPMG LLP as independent auditor for 2026. The proxy describes a classified Board structure, independent Board committees, executive and director pay, and robust governance policies, including an insider trading policy, clawback policy and prohibitions on hedging and pledging. Voting can be completed online, by phone, by mail or during the virtual meeting using a 16-digit control number.